Cytometric Characteristics and Proliferation of Inverted Papillomas of the Paranasal Sinuses

1996 ◽  
Vol 10 (1) ◽  
pp. 5-10 ◽  
Author(s):  
Gabriele I. Haibt-Lüttke ◽  
Hans J. Welkoborsky ◽  
Mike Hinni ◽  
Wolf J. Mann ◽  
Ronald G. Amedee
Keyword(s):  
Paranasal Sinuses ◽  
Proliferating Cell Nuclear Antigen ◽  
Dna Analysis ◽  
Nuclear Antigen ◽  
Primary Tumors ◽  
Primary Surgery ◽  
Proliferating Cell ◽  
Inverted Papillomas ◽  
Immunohistochemical Identification

Inverted papillomas are rare tumors of unknown histologic origin occurring in the nasal cavity and the paranasal sinuses. Specimens from 27 patients with histologically confirmed inverted papillomas were assessed by DNA analysis and immunohistochemical identification of the proliferating cell nuclear antigen (PCNA). One of the patients had squamous cell carcinoma associated with the inverted papilloma. According to the results of DNA analysis, patients with inverted papillomas would be divided into two groups. One group demonstrated low DNA indices and a low PCNA score. The second group showed higher DNA values associated with an increased proliferation rate. Two patients from each group developed recurrent disease. The recurrent papillomas from the patients in the first group demonstrated the same low DNA indices as were observed in the primary tumors. The recurrences from the patients in the second group occurred 1.5 and 2 years, respectively, following the primary surgery. Although the primary tumors had high DNA indices, the recurrences demonstrated a further increase of the DNA indices with cytological signs of malignancy. Quantitative DNA analysis and PCNA scoring offers a new, reliable means of assessing inverted papillomas and may possibly predict those tumors that behave more aggressively. Close follow up of patients presenting with high DNA indices and elevated PCNA scores is recommended.

Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma

1996 ◽  
Vol 84 (1) ◽  
pp. 85-90 ◽  
Author(s):  
Mark A. Cobb ◽  
Muhammad Husain ◽  
Bruce J. Andersen ◽  
Ossama Al-Mefty
Keyword(s):  
Proliferating Cell Nuclear Antigen ◽  
Statistical Significance ◽  
Tumor Biology ◽  
Nuclear Antigen ◽  
Intracranial Meningioma ◽  
Content Type ◽  
Tumor Histology ◽  
Proliferating Cell ◽  
Fine Print

✓ It is well known that the histological appearance of meningiomas often fails to predict accurately the clinical behavior of the tumor. Therefore, attention has turned from tumor histology to tumor biology. Proliferating cell nuclear antigen (PCNA), a cell cycle-regulated protein, has been recently characterized as the cofactor of DNA polymerase-δ, an enzyme required for DNA replication. The rate of synthesis of PCNA directly correlates with the proliferative state of cells. Immunohistochemical labeling of this antigen is now possible with monoclonal antibodies that allow for its demonstration in routinely fixed, paraffin-embedded specimens. In this study, the PCNA labeling index (LI) was determined for 83 meningiomas, including tumors with both benign and malignant clinical courses and with benign, atypical, and malignant histologies, apparent after total or subtotal resections. No statistical difference was found between the LI on recurrence and that found at initial presentation. In addition, stepwise multivariate regression analysis failed to identify any combination of factors (age, gender, race, age of specimen, tumor histology, Simpson grade of resection) that contributes to the predictive strength of the PCNA LI for tumor recurrence. However, for LIs less than 2%, only one of 26 gross totally resected tumors recurred (mean follow up 53 months); for LIs more than 7%, five of 13 gross totally resected tumors recurred (mean follow up 55 months). The difference in recurrence rates between gross totally resected meningiomas with PCNA LIs less than 2% and those with PCNA LIs more than 7% achieved statistical significance with a Fisher's exact probability equaling 0.011. The authors conclude that quantitative PCNA labeling of meningiomas is a promising technique that can provide meaningful prognostic information.

Proliferating Cell Nuclear Antigen Immunoreaction in Adrenal Tumors

1995 ◽  
Vol 81 (4) ◽  
pp. 273-277 ◽  
Author(s):  
Durval Damiani ◽  
Tais Della Manna ◽  
Luz G.W. Aquino ◽  
Vaê Dichtchekenian ◽  
Venâncio Avancini Ferreira Alves ◽  
...  
Keyword(s):  
Proliferating Cell Nuclear Antigen ◽  
Laboratory Data ◽  
Nuclear Antigen ◽  
Adrenal Tumors ◽  
State University ◽  
Pediatric Endocrinology ◽  
Kinetic Evaluation ◽  
Nuclear Antigens ◽  
Proliferating Cell

Aims and background We studied, retrospectively, 33 cases of adrenal tumors of children at the Pediatric Endocrinology Unit, Children's Institute, São Paulo State University Medical School, from 1975 to 1993. All patients had at least 2 years of follow-up with a few exceptions. Methods Clinical follow-up data were correlated with histopathologic review, laboratory data and cell kinetic evaluation (based on detection of proliferating cell nuclear antigens). Results With one exception, all the patients had presented signs of androgen production and had high levels of dehydro-epiandrosterone-sulfate. Tumor weight evaluation represented a good parameter of neoplasm evolution: of 19 cases weighing less than 250 g, 17 had no evidence of disease after surgery, and 2 had an unfavorable prognosis. Of 14 cases weighing more than 250 g, only 1 had no evidence of disease and 13 had an unfavorable evolution. Conclusions Proliferating cell nuclear antigen (PCNA) was not helpful to evaluate adrenal neoplasm evolution: our study did not show any correlation between PCNA score and prognosis.

Retinoblastoma protein and proliferating-cell nuclear antigen expression as predictors of recurrence in well-differentiated papillary thyroid carcinoma.

1997 ◽  
Vol 15 (12) ◽  
pp. 3458-3463 ◽  
Author(s):  
K Omura ◽  
A Nagasato ◽  
E Kanehira ◽  
H Kinsen ◽  
S Amaya ◽  
...  
Keyword(s):  
Proliferating Cell Nuclear Antigen ◽  
Recurrent Disease ◽  
Disease Free Survival ◽  
Expression Level ◽  
Nuclear Antigen ◽  
Primary Tumors ◽  
Free Survival ◽  
Well Differentiated ◽  
Proliferating Cell ◽  
Disease Free

PURPOSE We analyzed retinoblastoma protein (pRB) and proliferating-cell nuclear antigen (PCNA) expression in primary tumors and recurrent lesions of well-differentiated papillary thyroid carcinoma (PTC) to clarify the relationship between their expression and recurrent disease. PATIENTS AND METHODS The study included 93 patients with PTC. No recurrent disease had developed in 60 patients within 10 years after surgery (group N). Thirty patients in whom recurrent disease had developed after surgery were enrolled in group R. Levels of pRB and PCNA expression were quantified using the CAS 200 system (Cell Analysis Systems, Elmhurst, IL) following immunohistochemical staining. RESULTS Mean pRB expression level in the primary tumors in group R was significantly lower than that in group N (P < .0001). pRB expression in the tumors with a diameter up to 20 mm was significantly lower than that in tumors larger than 20 mm in group R (P < .01). There were no significant differences in the levels of expression of PCNA in the primary tumors between group N and group R. Univariate analysis demonstrated that the disease-free survival was significantly correlated with pN category, pRB, and PCNA expression level. The subgroup with high-level expression of pRB (> 25%) showed significantly long disease-free survival (P < .001). Furthermore, the subgroup with low-level expression of PCNA (< 35%) showed significantly longer disease-free survival (P < .05). Multivariate analysis showed pRB expression and pN category to be independent prognostic factors for disease-free survival in PTC. CONCLUSION pRB expression level can be used as a reliable predictor for recurrence of PTC.

Prognostic Indicators and Clinical Outcome in Dogs with Subcutaneous Mast Cell Tumors Treated with Surgery Alone: 43 Cases

2020 ◽  
Vol 56 (4) ◽  
pp. 215-225 ◽  
Author(s):  
Virginia Gill ◽  
Nicole Leibman ◽  
Sebastien Monette ◽  
Diane M. Craft ◽  
Philip J. Bergman
Keyword(s):  
Mast Cell ◽  
Clinical Outcome ◽  
Proliferating Cell Nuclear Antigen ◽  
Nuclear Antigen ◽  
Grading System ◽  
Nucleolar Organizer Regions ◽  
Low Grade ◽  
Mast Cell Tumors ◽  
Proliferating Cell

ABSTRACT The purpose of this study was to determine if clinical findings, histologic grade, or other histologic features were associated with clinical outcome in dogs with subcutaneous mast cell tumors (MCTs). Medical records of 43 client-owned dogs were retrospectively reviewed, and follow-up information was gathered via phone or follow-up examination. Progression-free survival (PFS), disease-free interval (DFI), and overall survival were calculated. Forty-two and twenty-two dogs, respectively, had grade 2 (Patnaik grading system) or low-grade tumors (two-tier grading system). Median PFS was 1474 days. Median DFI was not reached at &gt;1968 days. Overall median survival time was not reached at &gt;1968 days. In univariate analysis, argyrophilic nucleolar organizer regions (AgNORs), proliferating cell nuclear antigen, and mitotic index were negatively prognostic for PFS whereas Ki-67, proliferating cell nuclear antigen, and microvessel density were negatively prognostic for DFI. In multivariate analysis, AgNORs remained negatively prognostic for PFS. Results suggest that proliferation indices, especially AgNORs, may be useful in predicting the rare poor outcomes in dogs with subcutaneous MCTs. The vast majority of subcutaneous MCTs appear to be low or intermediate grade with excellent outcomes from good local tumor control.

scholarly journals Proliferating cell nuclear antigen antibody testing – getting them all

Pathology ◽  
2021 ◽  
Vol 53 ◽  
pp. S47
Author(s):  
Christine Bundell ◽  
Mathew Krummenacher ◽  
Elina Tan ◽  
Paul Sjollema ◽  
Nick Acquarola ◽  
...  
Keyword(s):  
Proliferating Cell Nuclear Antigen ◽  
Nuclear Antigen ◽  
Antibody Testing ◽  
Antigen Antibody ◽  
Proliferating Cell
Sign in / Sign up

Export Citation Format

Share Document